Current Clinical Applications of In Vivo Gene Therapy with AAVs is a research paper published in Molecular Therapy (2020). On theSindex it has a DataRank of 0.993. It has been cited 748 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.993
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: K08 HL 146991-01
Canadian Institutes of Health Research
Grant: 18059
NHLBI NIH HHS
Grant: K08 HL146991
NEI NIH HHS
Grant: R01 EY024280
FWCI
60.28
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 2 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 2 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 1 of A minimal bile salt excretory pump promoter allows bile acid-driven physiological regulation of transgene expression from a gene therapy vector
Additional file 1 of A minimal bile salt excretory pump promoter allows bile acid-driven physiological regulation of transgene expression from a gene therapy vector
Additional file 1 of Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice
Additional file 1 of Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice
Additional file 1 of Systematic in vivo candidate evaluation uncovers therapeutic targets for LMNA dilated cardiomyopathy and risk of Lamin A toxicity
Additional file 1 of Systematic in vivo candidate evaluation uncovers therapeutic targets for LMNA dilated cardiomyopathy and risk of Lamin A toxicity
Additional file 2 of Systematic in vivo candidate evaluation uncovers therapeutic targets for LMNA dilated cardiomyopathy and risk of Lamin A toxicity
Additional file 2 of Systematic in vivo candidate evaluation uncovers therapeutic targets for LMNA dilated cardiomyopathy and risk of Lamin A toxicity
Additional file 1 of Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2
Additional file 1 of Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2
Additional file 2 of Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2
Additional file 2 of Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2
Additional file 1 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 1 of In vivo rescue of genetic dilated cardiomyopathy by systemic delivery of nexilin
Additional file 1 of Comparative in vivo characterization of newly discovered myotropic adeno-associated vectors
Additional file 1 of Comparative in vivo characterization of newly discovered myotropic adeno-associated vectors
Additional file 2 of Comparative in vivo characterization of newly discovered myotropic adeno-associated vectors
Additional file 2 of Comparative in vivo characterization of newly discovered myotropic adeno-associated vectors